57238-76-3

Basic information

• Product Name: 5-(CHLOROMETHYL)-3-(4-METHOXYPHENYL)-1,2,4-OXADIAZOLE
• Synonyms: 5-(CHLOROMETHYL)-3-(4-METHOXYPHENYL)-1,2,4-OXADIAZOLE;AKOS BB-7029;BUTTPARK 97\16-92
• CAS NO: 57238-76-3
• Molecular Formula: C₁₀H₉ClN₂O₂
• Molecular Weight: 224.64
• Mol File: 57238-76-3.mol
• Article Data: 12

Chemical Properties

• Melting Point: 52 °C
• Boiling Point: 354.9 °C at 760 mmHg
• Flash Point: 168.4 °C
• Appearance: /
• Density: 1.278 g/cm³
• Vapor Pressure: 6.63E-05mmHg at 25°C
• Refractive Index: 1.547
• PKA: -1.87±0.37(Predicted)
• CAS DataBase Reference: 5-(CHLOROMETHYL)-3-(4-METHOXYPHENYL)-1,2,4-OXADIAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(CHLOROMETHYL)-3-(4-METHOXYPHENYL)-1,2,4-OXADIAZOLE(57238-76-3)
• EPA Substance Registry System: 5-(CHLOROMETHYL)-3-(4-METHOXYPHENYL)-1,2,4-OXADIAZOLE(57238-76-3)

Safety Data

• Hazard Codes: Xi:Irritant
• Statements: R36/37/38:Irritating to eyes, respiratory system and skin.
• Safety Statements: S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.; S37/39:Wear suitable g
• HazardClass: IRRITANT
• Hazardous Substances Data: 57238-76-3(Hazardous Substances Data)

Usage

General Description

5-(Chloromethyl)-3-(4-methoxyphenyl)-1,2,4-oxadiazole is a compound that belongs to the oxadiazole family of chemicals. It is a heterocyclic organic compound that contains both nitrogen and oxygen atoms in its five-membered ring structure. The chloromethyl group and the 4-methoxyphenyl group are attached to the 1,2,4-oxadiazole ring, giving the compound its specific chemical properties. This chemical has potential applications in the pharmaceutical industry, particularly in the development of new drugs and therapeutics due to its unique structural features. Its molecular structure and reactivity make it a valuable building block for the synthesis of various bioactive compounds. Additionally, its pharmacological and biological activities are areas of interest for further research and development.

InChI:InChI=1/C10H9ClN2O2/c1-14-8-4-2-7(3-5-8)10-12-9(6-11)15-13-10/h2-5H,6H2,1H3

Upstream product

• 5373-87-5 (Z)-N'-hydroxy-4-methoxybenzenecarboximidamide 
• 79-04-9 chloroacetyl chloride 
• 874-90-8 4-methoxybenzonitrile 
• 5373-87-5 4-methoxybenzamidoxime 

Downstream Products

• 73217-40-0 1-[3-(4-methoxy-phenyl)-[1,2,4]oxadiazol-5-ylmethyl]-pyridinium; chloride 
• 1304081-27-3 5-(azidomethyl)-3-(4-methoxyphenyl)-1,2,4-oxadiazole 

Relevant articles and documents

Synthesis of Some Azamacrocycles Bearing 1,2,4-Oxadiazole and 1,2,3-Triazole Moieties

Abstract: A tetraazacrown ether,4,9-di(prop-2-yn-1-yl)-1,4,9,12-tetraazacyclohexadecane-2,11-dione, bearingpropargyl groups on two nitrogens was synthesized starting from1,4,9,12-tetraazacyclohexadecane-2,11-dione and subjected to 1,3-cycloadditionreactio

Design, synthesis, pharmacological evaluation, and docking study of new acridone-based 1,2,4-oxadiazoles as potential anticonvulsant agents

A number of acridone-based oxadiazoles 11a–n have been synthesized and evaluated for their anticonvulsant activity against pentylenetetrazole (PTZ)- and maximal electroshock (MES)-induced seizures in mice. Also, their neurotoxicity was evaluated by the rotarod test. Most of the compounds exhibited better anticonvulsant activity and higher safety respect to the standard drug, phenobarbital. Among the tested derivatives, compounds 11l with ED50value of 2.08?mg/kg was the most potent compound in the PTZ test. The anticonvulsant effect of compound 11l was blocked by flumazenil, suggesting the involvement of benzodiazepine (BZD) receptors in the anticonvulsant activity of prototype compound 11l. Also, docking study of compound 11l in the BZD-binding site of GABAAreceptor confirms possible binding of compound 11l with BZD receptors.

Design, synthesis, biological evaluation, and docking study of acetylcholinesterase inhibitors: New acridone-1,2,4-oxadiazole-1,2,3-triazole hybrids

In this study, novel acridone-1,2,4-oxadiazole-1,2,3-triazole hybrids were designed, synthesized, and evaluated for their acetylcholinesterase and butyrylcholinesterase inhibitory activity. Among various synthesized compounds, 10-((1-((3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl)methyl)-1H-1,2,3-triazol-4-yl)methyl)acridin-9(10H)-one 10b showed the most potent anti-acetylcholinesterase activity (IC50 = 11.55 μm) being as potent as rivastigmine. Also docking outcomes were in good agreement with in vitro results confirming the dual binding inhibitory activity of compound 10b. A novel series of acridone-1,2,4-oxadiazole-1,2,3-triazole hybrids were synthesized and evaluated in vitro for their acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activities.